Clinical Trial

TmPSMA-02 in mCRPC

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-11
Trial Details
NCT Number NCT06046040
Lead Sponsor University of Pennsylvania
Collaborators: Prostate Cancer Foundation
Conditions Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment 30 participants
Start Date 2024-01-31
Primary Completion 2027-01-31 (estimated)
Study Completion 2042-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10